#atezo bev hcc

[yeshealthplease]

Drug 'breakthrough' gives longest-ever survival in nonresectable liver cancer patients

Drug ‘breakthrough’ gives longest-ever survival in nonresectable liver cancer patients

The IMbrave150 trial found median overall survival was 19.2 months in patients treated with atezo+bev vs 13.4 months for those treated with sorafenib alone, the current standard treatment (HR, 0.66 [95% CI, 0.52-0.85]; P=0.0009). Survival at 18 months was 52% with atezo+bev and 40% in patients treated with sorafenib. All patients in the trial had nonresectable HCC—the most common form of liver…

View On WordPress

#Breakthrough #Cancer #drug #liver #longestever #nonresectable #patients #survival